{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:50:13Z","timestamp":1793065813132,"version":"4.5.0"},"reference-count":10,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"abstract":"<jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>Little is known about glucagon-like peptide-1 receptor agonists (GLP1RAs) use in multiple sclerosis. We described the frequency and characteristics associated with use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional survey of NARCOMS Registry participants captured use of GLP1RAs semaglutide and tirzepatide. Multivariable logistic regression explored factors associated with use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 4181 eligible participants, 7.4% had ever and 5.5% currently used these GLP1RAs. Ever users were younger and had more cardiometabolic conditions. 37.3% of never users had an indication for GLP1RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Despite 40% having an indication for taking GLP1RAs, a small percentage of surveyed persons with multiple sclerosis used them.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261442033","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:56:16Z","timestamp":1777467376000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of semaglutide and tirzepatide among people with multiple sclerosis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1088-110X","authenticated-orcid":false,"given":"Amber","family":"Salter","sequence":"first","affiliation":[{"name":"Department of Neurology, Section on Biostatistics and Clinical Informatics, UT Southwestern, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5445-8313","authenticated-orcid":false,"given":"Alexis","family":"Novak","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8871-7134","authenticated-orcid":false,"given":"Samantha","family":"Lancia","sequence":"additional","affiliation":[{"name":"Department of Neurology, Section on Biostatistics and Clinical Informatics, UT Southwestern, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-980X","authenticated-orcid":false,"given":"Gary R","family":"Cutter","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama in Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-3717","authenticated-orcid":false,"given":"Robert J","family":"Fox","sequence":"additional","affiliation":[{"name":"Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1855-5595","authenticated-orcid":false,"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada; Department of Medicine, Nova Scotia Health, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Montero ASG Presiado M Hamel L. KFF health tracking poll May 2024: The public\u2019s use and views of GLP-1 drugs https:\/\/www.kff.org\/health-costs\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/ (2024)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07701-7"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106229"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2020-133"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2021-102"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000311013"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/dca25-0090"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2021-007"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2920"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333465"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261442033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261442033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261442033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:18:23Z","timestamp":1777792703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261442033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":10,"alternative-id":["10.1177\/13524585261442033"],"URL":"https:\/\/doi.org\/10.1177\/13524585261442033","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"13524585261442033"}}